Glenmark Pharmaceuticals expecting nod from USFDA
Glenmark Pharmaceuticals has recently stated to PTI that during this fiscal the company is expecting a go-ahead from the US Food and Drug Administration (USFDA) for four to six new products.After getting approval for 8 new products earlier this year, this fiscal the company is expected to launch Teneligliptin, a new third generation oral anti-diabetic agent, is used for the management of Type...
Login or Register to read the full article
Glenmark Pharmaceuticals has recently stated to PTI that during this fiscal the company is expecting a go-ahead from the US Food and Drug Administration (USFDA) for four to six new products.
After getting approval for 8 new products earlier this year, this fiscal the company is expected to launch Teneligliptin, a new third generation oral anti-diabetic agent, is used for the management of Type 2 Diabetes Mellitus.
Glenmark has launched this molecule under two brands, Ziten and Zita Plus, at Rs 19.90 per tablet.
"... the launch of these two products will lower the daily cost of treatment for a diabetes patient on Gliptin therapy by approximately 55 per cent," Glenmark Pharmaceuticals President and Head-India Business Sujesh Vasudevan told the reporters.
Glenmark's diabetes segment is valued at around Rs 100 crore, Vasudevan said, adding it is growing at 20 per cent per annum.
After getting approval for 8 new products earlier this year, this fiscal the company is expected to launch Teneligliptin, a new third generation oral anti-diabetic agent, is used for the management of Type 2 Diabetes Mellitus.
Glenmark has launched this molecule under two brands, Ziten and Zita Plus, at Rs 19.90 per tablet.
"... the launch of these two products will lower the daily cost of treatment for a diabetes patient on Gliptin therapy by approximately 55 per cent," Glenmark Pharmaceuticals President and Head-India Business Sujesh Vasudevan told the reporters.
Glenmark's diabetes segment is valued at around Rs 100 crore, Vasudevan said, adding it is growing at 20 per cent per annum.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd